Johnson & Johnson’s highest Q1 estimate, boosting sales outlook throughout the year
Christina Arias/Cover/Getty Images
Johnson and Johnson (jnj) reported better-than-expected first-quarter results on Tuesday and canceled sales forecasts for an entire year.
The pharmaceutical and medical technology company’s earnings per share adjusted revenue was $2.77, with revenue of $21.89 billion. According to estimates compiled by Visible Alpha, analysts’ expectations are $2.56 and $21.56 billion, respectively.
After the report, Johnson and Johnson’s shares rose by about 1%. They have entered about 7% of the time since the beginning of the year.
The company increased its estimated sales to $91 billion to $91.8 billion, from the previous $89.2 billion to $90 billion. It also puts adjusted EPS forecast steady at $10.50 to $10.70, “includes tariff charges, dilution of intracellular therapy, and updated forex trading.”
Since reporting disappointing 2025 sales outlook in January, the company has acquired nearly $15 billion in intracellular therapy and announced plans to increase its investment to more than $55 billion over the next four years.
Johnson and Johnson shares earlier this month after a judge denied its proposed “pre-packaged bankruptcy plan” subsidiary, which will settle thousands of claims accusing its talc powder of cancer.
Read the original article about Investopedia
